Skip to main
MBX

MBX Stock Forecast & Price Target

MBX Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 10%

Bulls say

MBX Biosciences Inc has demonstrated positive clinical outcomes through its proprietary Precision Endocrine Peptide platform, with canvuparatide achieving a statistically significant 63% composite response at 12 weeks and a 79% responder rate at six months in open-label extension (OLE) studies, showcasing its potential efficacy. The company has shown strong patient enthusiasm with a 94% entry rate into OLE, further validating the safety and tolerability of canvuparatide, which is important for long-term treatment options. Updated financial models reflect increased confidence in significant market potential, with the company's management asserting that canvuparatide could achieve blockbuster sales, influenced by its favorable dosing regimen and effectiveness in managing key metabolic markers.

Bears say

MBX Biosciences Inc faces significant downside risks that may adversely impact its stock performance, particularly related to the efficacy and safety outcomes of Phase 2 and Phase 3 clinical trials for its lead product candidates. Potential delays in research and development, regulatory approvals, or commercial development processes could further hinder the company’s progress and financial outlook. Additionally, the threat of competition within the peptide therapy market, including the emergence of new competitors and the performance of existing market entities, raises concerns regarding the potential for market share erosion and unmet expectations from competitor product launches.

MBX has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 10% predict a Strong Sell.

This aggregate rating is based on analysts' research of MBX Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MBX Biosciences Inc (MBX) Forecast

Analysts have given MBX a Buy based on their latest research and market trends.

According to 10 analysts, MBX has a Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $54.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $54.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MBX Biosciences Inc (MBX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.